| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (NCT05218408) | Celularity Incorporated | 2021-09-01 |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM (NCT04489420) | Celularity Incorporated | 2020-10-01 |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma (NCT03014804) | Jonsson Comprehensive Cancer Center | 2019-12-01 |
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma (NCT03027388) | National Cancer Institute (NCI) | 2019-01-09 |
| Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma (NCT02709226) | National Cancer Institute (NCI) | 2016-06-15 |
| DC Migration Study for Newly-Diagnosed GBM (NCT02366728) | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 2015-10-12 |
| Vaccine Therapy in Treating Patients With Recurrent Glioblastoma (NCT03360708) | Mayo Clinic | 2013-11-27 |
| Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (NCT01957956) | Mayo Clinic | 2013-11-11 |
| p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors (NCT01975116) | Pediatric Brain Tumor Consortium | 2013-08-01 |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (NCT01836549) | Pediatric Brain Tumor Consortium | 2013-03-01 |
| Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (NCT01250470) | Roswell Park Cancer Institute | 2012-09-05 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (NCT01609790) | National Cancer Institute (NCI) | 2012-06-04 |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas (NCT01514201) | National Cancer Institute (NCI) | 2012-02-01 |
| A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (NCT01498328) | Celldex Therapeutics | 2011-12-01 |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (NCT01480479) | Celldex Therapeutics | 2011-11-01 |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 (NCT01082926) | City of Hope Medical Center | 2010-05-01 |
| Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma (NCT01149850) | Jonsson Comprehensive Cancer Center | 2010-04-28 |
| Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma (NCT00960492) | Exelixis | 2009-09-01 |
| Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM (NCT00943462) | Centre hospitalier de l'Université de Montréal (CHUM) | 2009-06-01 |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma (NCT01095094) | Case Comprehensive Cancer Center | 2009-01-01 |